These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9533776)

  • 1. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo.
    Lydon NB; Mett H; Mueller M; Becker M; Cozens RM; Stover D; Daniels D; Traxler P; Buchdunger E
    Int J Cancer; 1998 Mar; 76(1):154-63. PubMed ID: 9533776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
    Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
    Major TC; Keiser JA
    J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
    Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
    Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin.
    Cassinelli G; Lanzi C; Pensa T; Gambetta RA; Nasini G; Cuccuru G; Cassinis M; Pratesi G; Polizzi D; Tortoreto M; Zunino F
    Biochem Pharmacol; 2000 Jun; 59(12):1539-47. PubMed ID: 10799650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.
    Buchdunger E; Trinks U; Mett H; Regenass U; Müller M; Meyer T; McGlynn E; Pinna LA; Traxler P; Lydon NB
    Proc Natl Acad Sci U S A; 1994 Mar; 91(6):2334-8. PubMed ID: 8134396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors.
    Yaish P; Gazit A; Gilon C; Levitzki A
    Science; 1988 Nov; 242(4880):933-5. PubMed ID: 3263702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.
    Gazit A; Yaish P; Gilon C; Levitzki A
    J Med Chem; 1989 Oct; 32(10):2344-52. PubMed ID: 2552117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin.
    Korutla L; Cheung JY; Mendelsohn J; Kumar R
    Carcinogenesis; 1995 Aug; 16(8):1741-5. PubMed ID: 7634398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
    Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
    Discafani CM; Carroll ML; Floyd MB; Hollander IJ; Husain Z; Johnson BD; Kitchen D; May MK; Malo MS; Minnick AA; Nilakantan R; Shen R; Wang YF; Wissner A; Greenberger LM
    Biochem Pharmacol; 1999 Apr; 57(8):917-25. PubMed ID: 10086326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor.
    Fry DW; Nelson JM; Slintak V; Keller PR; Rewcastle GW; Denny WA; Zhou H; Bridges AJ
    Biochem Pharmacol; 1997 Oct; 54(8):877-87. PubMed ID: 9354588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
    Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
    J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genistein and erbstatin inhibition of normal mammary epithelial cell proliferation is associated with EGF-receptor down-regulation.
    McIntyre BS; Sylvester PW
    Cell Prolif; 1998 Feb; 31(1):35-46. PubMed ID: 9666817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
    Garcia R; Bowman TL; Niu G; Yu H; Minton S; Muro-Cacho CA; Cox CE; Falcone R; Fairclough R; Parsons S; Laudano A; Gazit A; Levitzki A; Kraker A; Jove R
    Oncogene; 2001 May; 20(20):2499-513. PubMed ID: 11420660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.